SCHEMBL2325145

SCHEMBL2325145

COP(=O)(CC(=O)c1ccc(F)cc1C)OC

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.39
NPC1 O15118 4/20 0.36
RAB9A P51151 4/20 0.36
MAPT P10636 3/20 0.36
KMT2A Q03164 3/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
CES2 O00748 1/20 0.36
CES1 P23141 1/20 0.36
MMP1 P03956 2/20 0.36
MAPK14 Q16539 1/20 0.36
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
USP2 O75604 1/20 0.35
TP53 P04637 1/20 0.35
ALOX15 P16050 1/20 0.35
ALOX12 P18054 1/20 0.35
HSD17B10 Q99714 1/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.34
POLB P06746 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2324606 0.86 CES2 (0.49) RAB9ACES2CES1ALDH1A1GAA
SCHEMBL2322299 0.84 TAS1R3 (0.46) HTTNPC1RAB9AMAPTKMT2A
SCHEMBL1549680 0.84 PYGL (0.44) NPC1RAB9AKMT2AMEN1ALOX15
SCHEMBL2324769 0.83 CES2 (0.49) HTTNPC1RAB9AMAPTKMT2A
SCHEMBL2329635 0.82 FLT1 (0.43) HTTNPC1RAB9AMAPTSMN1; SMN2
SCHEMBL1550115 0.81 KMT2A (0.40) NPC1RAB9AMAPTKMT2ASMN1; SMN2
SCHEMBL2331695 0.81 SMN1; SMN2 (0.43) HTTNPC1RAB9AMAPTKMT2A
SCHEMBL2322443 0.79 LMNA (0.50) HTTNPC1RAB9AMAPTKMT2A
SCHEMBL2325106 0.78 EPHX2 (0.38) HTTCES2CES1MRGPRX4
SCHEMBL2325155 0.78 TSHR (0.36) HTTNPC1RAB9AMAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904455-B1 PYRIDAZINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-08-17 EP disclosed
US-7678795-B2 Pyridazines as 11b-HSD1 inhibitors HOFFMAN-LA ROCHE INC. (US) 2010-03-16 US disclosed
EP-1904455-A2 PYRIDAZINE DERIVATIVES F. Hoffmann-Roche AG (CH) 2008-04-02 EP disclosed
US-20070010519-A1 New pyridazines as 11B-HSD1 inhibitors HOFFMANN-LA ROCHE INC. 2007-01-11 US disclosed
WO-2007003521-A2 PYRIDAZINE DERIVATIVES AS 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2007-01-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010519-A1 New pyridazines as 11B-HSD1 inhibitors HSD11B1, HSD17B1, HSD17B11 HTT 3917/4885NPC1 655/4885RAB9A 3579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.